168 related articles for article (PubMed ID: 31251079)
1. Elevated
Bravo-Navas S; Yáñez L; Romón Í; Pipaón C
FASEB J; 2019 Sep; 33(9):10477-10489. PubMed ID: 31251079
[TBL] [Abstract][Full Text] [Related]
2. Long intergenic non-coding RNA-p21 is associated with poor prognosis in chronic lymphocytic leukemia.
Abo Elwafa R; Abd Elrahman A; Ghallab O
Clin Transl Oncol; 2021 Jan; 23(1):92-99. PubMed ID: 32468342
[TBL] [Abstract][Full Text] [Related]
3. Genomic amplification of Fanconi anemia complementation group A (FancA) in head and neck squamous cell carcinoma (HNSCC): Cellular mechanisms of radioresistance and clinical relevance.
Hess J; Unger K; Orth M; Schötz U; Schüttrumpf L; Zangen V; Gimenez-Aznar I; Michna A; Schneider L; Stamp R; Selmansberger M; Braselmann H; Hieber L; Drexler GA; Kuger S; Klein D; Jendrossek V; Friedl AA; Belka C; Zitzelsberger H; Lauber K
Cancer Lett; 2017 Feb; 386():87-99. PubMed ID: 27867017
[TBL] [Abstract][Full Text] [Related]
4. p53 protein expression in chronic lymphocytic leukemia.
Sellmann L; Carpinteiro A; Nückel H; Scholtysik R; Siemer D; Klein-Hipass L; Kube D; Dürig J; Dührsen U; Stanelle J; Küppers R
Leuk Lymphoma; 2012 Jul; 53(7):1282-8. PubMed ID: 22220854
[TBL] [Abstract][Full Text] [Related]
5. Mantle cell lymphoma-variant Richter syndrome: Detailed molecular-cytogenetic and backtracking analysis reveals slow evolution of a pre-MCL clone in parallel with CLL over several years.
Klener P; Fronkova E; Berkova A; Jaksa R; Lhotska H; Forsterova K; Soukup J; Kulvait V; Vargova J; Fiser K; Prukova D; Alam M; Calvin Lenyeletse Maswabi B; Michalova K; Zemanova Z; Jancuskova T; Pekova S; Trneny M
Int J Cancer; 2016 Nov; 139(10):2252-60. PubMed ID: 27407063
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia.
Saddler C; Ouillette P; Kujawski L; Shangary S; Talpaz M; Kaminski M; Erba H; Shedden K; Wang S; Malek SN
Blood; 2008 Feb; 111(3):1584-93. PubMed ID: 17971485
[TBL] [Abstract][Full Text] [Related]
7. Increased transferrin receptor expression following 11q23 deletion as a mechanism of malignant progression in chronic lymphocytic leukemia.
Shackelford RE; Bhalodia AR; Cotelingam JD; Veillon DM; Lowery-Nordberg M
Med Hypotheses; 2006; 66(3):509-12. PubMed ID: 16326028
[TBL] [Abstract][Full Text] [Related]
8. Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia.
Knittel G; Rehkämper T; Korovkina D; Liedgens P; Fritz C; Torgovnick A; Al-Baldawi Y; Al-Maarri M; Cun Y; Fedorchenko O; Riabinska A; Beleggia F; Nguyen PH; Wunderlich FT; Ortmann M; Montesinos-Rongen M; Tausch E; Stilgenbauer S; P Frenzel L; Herling M; Herling C; Bahlo J; Hallek M; Peifer M; Buettner R; Persigehl T; Reinhardt HC
Nat Commun; 2017 Jul; 8(1):153. PubMed ID: 28751718
[TBL] [Abstract][Full Text] [Related]
9. Bulky lymphadenopathy with poor clinical outcome is associated with ATM downregulation in B-cell chronic lymphocytic leukemia patients irrespective of 11q23 deletion.
Joshi AD; Dickinson JD; Hegde GV; Sanger WG; Armitage JO; Bierman PJ; Bociek RG; Devetten MP; Vose JM; Joshi SS
Cancer Genet Cytogenet; 2007 Jan; 172(2):120-6. PubMed ID: 17213020
[TBL] [Abstract][Full Text] [Related]
10. The BH3-only protein Puma plays an essential role in p53-mediated apoptosis of chronic lymphocytic leukemia cells.
Zhu HJ; Liu L; Fan L; Zhang LN; Fang C; Zou ZJ; Li JY; Xu W
Leuk Lymphoma; 2013 Dec; 54(12):2712-9. PubMed ID: 23517560
[TBL] [Abstract][Full Text] [Related]
11. The potential anticancer agent PK11195 induces apoptosis irrespective of p53 and ATM status in chronic lymphocytic leukemia cells.
Santidrián AF; Cosialls AM; Coll-Mulet L; Iglesias-Serret D; de Frias M; González-Gironès DM; Campàs C; Domingo A; Pons G; Gil J
Haematologica; 2007 Dec; 92(12):1631-8. PubMed ID: 18055986
[TBL] [Abstract][Full Text] [Related]
12. Molecular basis of aggressive disease in chronic lymphocytic leukemia patients with 11q deletion and trisomy 12 chromosomal abnormalities.
Mittal AK; Hegde GV; Aoun P; Bociek RG; Dave BJ; Joshi AD; Sanger WG; Weisenburger DD; Joshi SS
Int J Mol Med; 2007 Oct; 20(4):461-9. PubMed ID: 17786276
[TBL] [Abstract][Full Text] [Related]
13. Induction of TAp73 by platinum-based compounds to overcome drug resistance in p53 dysfunctional chronic lymphocytic leukemia.
Tonino SH; Mulkens CE; van Laar J; Derks IA; Suo G; Croon-de Boer F; van Oers MH; Eldering E; Wang JY; Kater AP
Leuk Lymphoma; 2015; 56(8):2439-47. PubMed ID: 25511680
[TBL] [Abstract][Full Text] [Related]
14. Immunocytochemical detection of bcl-2 and p53 proteins in B-chronic lymphocytic leukemia patients.
Klobusická M; Kusenda J; Babusíková O
Neoplasma; 2002; 49(6):387-93. PubMed ID: 12584586
[TBL] [Abstract][Full Text] [Related]
15. Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic lymphocytic leukaemia cells.
Lin K; Rockliffe N; Johnson GG; Sherrington PD; Pettitt AR
Oncogene; 2008 Apr; 27(17):2445-55. PubMed ID: 17982489
[TBL] [Abstract][Full Text] [Related]
16. MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.
Gryshchenko I; Hofbauer S; Stoecher M; Daniel PT; Steurer M; Gaiger A; Eigenberger K; Greil R; Tinhofer I
J Clin Oncol; 2008 May; 26(14):2252-7. PubMed ID: 18467716
[TBL] [Abstract][Full Text] [Related]
17. p53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis.
Cordone I; Masi S; Mauro FR; Soddu S; Morsilli O; Valentini T; Vegna ML; Guglielmi C; Mancini F; Giuliacci S; Sacchi A; Mandelli F; Foa R
Blood; 1998 Jun; 91(11):4342-9. PubMed ID: 9596683
[TBL] [Abstract][Full Text] [Related]
18. Aberrant nuclear p53 expression predicts hemizygous 17p (TP53) deletion in chronic lymphocytic leukemia.
Chang H; Jiang AM; Qi CX
Am J Clin Pathol; 2010 Jan; 133(1):70-4. PubMed ID: 20023260
[TBL] [Abstract][Full Text] [Related]
19. CD markers variations in chronic lymphocytic leukemia: New insights into prognosis.
Vosoughi T; Bagheri M; Hosseinzadeh M; Ehsanpour A; Davari N; Saki N
J Cell Physiol; 2019 Nov; 234(11):19420-19439. PubMed ID: 31049958
[TBL] [Abstract][Full Text] [Related]
20. Chronic lymphocytic leukemia with TP53 gene alterations: a detailed clinicopathologic analysis.
Liu YC; Margolskee E; Allan JN; Mathew S; Bhavsar E; Casano J; Orazi A; Furman RR; Geyer JT
Mod Pathol; 2020 Mar; 33(3):344-353. PubMed ID: 31477813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]